Skip to content
Screener

Arvinas ARVN Common Stock

Common Stock at other companies

Nurix Therapeutics, Inc. logo
Nurix Therapeutics, Inc.NRIX
500M0.0%
LON
LeonaBio, Inc.LONA
$1K-75.0%
Kymera Therapeutics logo
Kymera TherapeuticsKYMR
$8K+14.3%
Monte Rosa Therapeutics, Inc. logo
Monte Rosa Therapeutics, Inc.GLUE
$9K+50.0%
Relmada Therapeutics, Inc. logo
Relmada Therapeutics, Inc.RLMD
150M0.0%
ArriVent BioPharma, Inc. logo
ArriVent BioPharma, Inc.AVBP
$5K+25.0%

Other financials

Income statement

See full
Revenue$15.6M-91.7%
Operating income-$63.8M-189%
Net income-$57.6M-169%
EPS (diluted)-$0.90-179%

Balance sheet

See full
Cash & equivalents$87.3M+7.8%
Total debt$8.6M-19.6%
Total equity$386.8M-41.4%
Total assets$647.5M-35.3%

Cash flow

See full
Operating cash flow-$69.2M+22.2%
CapEx$1.3M+225%
Free cash flow-$70.5M+21.1%

Valuation

See full
Market cap$587.82M+21.6%
Enterprise value$509.12M+34.5%
P/S6.6×+5.3×

Profitability

See full
Operating margin-283.8%-310pp
Net margin-247.5%-260pp
FCF margin-287.4%

Returns & leverage

See full
Return on equity-42.3%-53.5pp
Debt / equity0.0×
Current ratio5.4×+0.9×

Where this comes from

Reported directly by Arvinas in its filing.

Tagged under the XBRL concept us-gaap:CommonStockValue.

The source filing: Arvinas’s 10-Q, filed May 11, 2026.

Filed
May 11, 2026, 5:18 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001628280-26-033669
(dollars and shares in millions, except per share amounts)March 31,2026December 31,2025
Commitments and Contingencies (Note 12)
Stockholders’ equity:
Preferred stock, $0.001 par value, zero shares issued and outstanding as of March 31, 2026 and December 31, 2025, respectively
Common stock, $0.001 par value; 74.5 shares issued and 64.5 shares outstanding as of March 31, 2026, and 73.5 shares issued and 63.5 outstanding as of December 31, 20250.10.1
Accumulated deficit(1,670.0)(1,612.4)
Additional paid-in capital2,149.02,136.9
Accumulated other comprehensive (loss) income(0.4)1.2
Treasury Stock, at cost (10.0 shares as of March 31, 2026 and December 31, 2025)(91.9)(91.9)

Item 1. Financial Statements (Unaudited)

FAQ

What is Arvinas's common stock?
Arvinas (ARVN) reported common stock of $100K in Q1 2026.
How has Arvinas's common stock changed year-over-year?
Arvinas's common stock decreased by 0.0% year-over-year, from $100K to $100K.
What does common stock mean?
The par value of all common shares issued and outstanding, typically a nominal amount ($0.01 or $0.001 per share).

Ask your AI about Arvinas's common stock.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude